---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292803852.md"
description: "Veradermics shares are trading higher after the company released topline results from an open-label Phase 2 trial evaluating its experimental VDPHL01 in women with mild-to-moderate pattern hair loss. Also, Needham maintained its Buy rating on the stock and raised its price target from $136 to $164."
datetime: "2026-07-15T17:49:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292803852.md)
  - [en](https://longbridge.com/en/news/292803852.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292803852.md)
generator: "portal-rs"
---

# 

Veradermics shares are trading higher after the company released topline results from an open-label Phase 2 trial evaluating its experimental VDPHL01 in women with mild-to-moderate pattern hair loss. Also, Needham maintained its Buy rating on the stock and raised its price target from $136 to $164.

### Related Stocks

- [MANE.US](https://longbridge.com/en/quote/MANE.US.md)

## Related News & Research

- [Veradermics to Present at Upcoming September Investor Conferences | MANE Stock News](https://longbridge.com/en/news/297961665.md)
- [Veradermics to discuss Phase 2 results for oral minoxidil hair-loss drug VDPHL01 on July 15 webcast](https://longbridge.com/en/news/292682761.md)
- [Can Absci’s (ABSI) Low-Frequency Hair Loss Therapy Redefine Its Long-Term Platform Potential?](https://longbridge.com/en/news/297731951.md)
- [Tyra Biosciences to present initial Phase 2 SURF302 data for oral dabogratinib in intermediate-risk bladder cancer on Sept. 9](https://longbridge.com/en/news/298034950.md)
- [06:00 ETBest Minoxidil for Women (2026): Happy Head Recognized for Personalized Minoxidil Formulas by Consumer365](https://longbridge.com/en/news/298199996.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**